我们Elekta团结磁共振辐射其他apy (MR/RT) system took the silver award for radiation treatment advancements in the medical/dental category in the 2020 Edison Awards. Among the nomination entries comprising the best products, services, and businesses in innovation for the year 2020, Unity was chosen as a winner by a panel of over 3,000 leading business executives from around the world.
The Edison Awards is an annual competition honoring excellence in new product and service development, marketing, human-centered design, and innovation. Elekta Unity is a paradigm shift for precision radiation medicine. Unity’s breakthrough technology is designed to provide the best outcomes for patients while meeting the needs of the cancer care team delivering treatment, fully in the spirit of Edison, a truly breakthrough inventor.
Elekta’s MOSAIQ® Oncology Information System has been selected as Category Leader in the Oncology-Radiation category in the 2020 Best in KLAS: Software and Services Report. Awards are based on evaluations collected by KLAS, an independent research firm.
Receiving the Category Leader award for MOSAIQ highlights Elekta’s leadership in radiation oncology software. MOSAIQ, a seven-time KLAS Category Leader, is more than an electronic health record; it is part of a comprehensive suite of innovative digital tools – calledMOSAIQ Plaza– that works seamlessly with Elekta radiotherapy systems to provide the foundation for intelligence-driven, value-based healthcare. With MOSAIQ Plaza, healthcare professionals are connected to their patients through every step of their treatment journey – ensuring efficient, standardized daily practice that streamlines patients’ care and optimizes treatment outcomes.
Elekta’sVersa HD™ linear acceleratorhas been selected as Category Leader in the Radiation Therapy category in the 2020 Best in KLAS: Software and Services Report. Awards are based on evaluations collected by KLAS, an independent research firm.
Receiving the Category Leader award for Versa HD highlights Elekta’s leadership in innovating radiation therapy delivery systems. Under evolving, value-based care approaches in radiation oncology, the trend toward paying for complete episodes of care aligns well with a growing body of data demonstrating that hypofractionated regimens can provide excellent outcomes while reducing the number of treatment sessions needed to deliver a complete radiation dose. Versa HD’s stereotactic capabilities and ability to hypofractionate treatment regimens have a demonstrated ability to achieve these objectives.
我们很自豪共享Elekta的获胜者the 'Excellence in Innovation Award' at the 2019 Swedish Business in Australia Awards, sponsored by the Swedish Australian Chamber of Commerce (SACC). SACC has been established in Australia since 1911, more than 100 years and creates a sustainable network among the Swedish and Australian companies in Australia.
This innovation award for Elekta Unity shows it continues to be recognized as breakthrough technology for cancer patients. The MR-linac is one of the most important radiotherapy innovations for patients with cancer, enabling clear visualization of the tumor and surrounding healthy tissues during beam delivery and the ability to adapt the treatment in real time based on daily changes to the tumor’s position, size and shape.
Elekta wins one of the highest honors in the category of field service, recognizing commitment to outstanding innovation, leadership, and excellence a great honor in the technology services industry. The award recognizes commitment to outstanding innovation, leadership and excellence, and highlights best practices across industries. With this accolade, the TSIA acknowledges Elekta as an industry leader in Field Service.
Elekta continues to invest in solutions like Elekta IntelliMax, a proactive and an increasingly predictive software that solves problems before they happen to reduce unplanned clinical downtime, which is good for our customers and their patients. This further emphasizes the quality and commitment of our extended global services team to deliver exceptional support to each Elekta customer.
Elekta has been awarded the Institute of Physics (IOP) Business Innovation Award 2019 for Elekta Unity magnetic resonance radiation therapy (MR/RT) system. The IOP Business Awards are the only awards recognizing companies in the UK and Ireland that have built success on the innovative application of physics.
The Award is a tremendous mark of recognition that the recipient company is at the cutting edge of physics and business. This award underscores Elekta’s innovative spirit and ability to fuse its passion for cutting edge science with its fifty-year commitment to improving patient outcomes. We thank the members of the Elekta MR-Linac Consortium for the groundbreaking contributions they made to the technologic development of Elekta Unity.
Elekta Unity is CE-marked and 510(k) cleared. Not commercially available in all markets.
MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health and medical technology market, has presented the “Medical Device Engineering Breakthrough” award in the 2019 MedTech Breakthrough Awards program to Elekta for its Elekta Unity MR-linac.
Why is this important?
This annual award recognizes outstanding health and medical technology products and companies. Elekta Unity is a shining example of groundbreaking medical technology deserving of this designation by displaying breakthrough engineering that combines precision radiation therapy and high-field MR imaging, Elekta Unity addresses one of the most critical healthcare issues in the world with a focus on providing the next generation of cancer care.
Elekta and DCA Design International Ltd. are the winners of the Red Dot Award: Product Design 2019, one of the world’s largest design competitions. Elekta Unity was crafted as the result of meticulous research contributed by clinicians using the technology each day. A panel of experienced and expert jurors have individually reviewed each of the more than 5,500 products entered and have reached a joint decision on which products will receive this Red Dot distinction.
Why is this important?
The prestigious Red Dot award further underlines the real benefits of an intelligent evidence-based design approach in delivering success and illustrates Elekta’s commitment to designing patient-centric technologies that allow clinicians to deliver the best quality cancer care worldwide.
Elekta has been recognized by MD Buyline as the industry leader in Service Response Time for radiation therapy treatment delivery systems for five consecutive quarters. Hospitals and health systems nationwide recognize MD Buyline as the leading provider of unbiased, evidence-based clinical and financial insight and information.
Why is this important?
Fast onsite support is just one of the features of Elekta Care, our comprehensive services program designed to support you throughout your entire Elekta experience. When help is needed, our onsite support is ready for a fast response. We know what an hour means to you and your patients.
Elekta offers a wide range of offerings designed to get new solutions up and running quickly, maximize asset uptime, optimize utilization and help keep current with changing technologies. Learn morehere.
MD Buyline user satisfaction survey radiation therapy treatment delivery systems. Q1 18 – Q4 18
Elekta’s role in influencing and driving positive change in business and society was recognized by the Ethisphere Institute – a global leader in defining and advancing the standards of ethical business practices – as one of2019 World’s Most Ethical Companies® Elekta was among 128 honorees recognized in 21 countries and 50 industries.
Why is this important?
Elekta stakeholders need to trust that the company adheres to strict business ethics, which is a key focus in Elekta’s compliance program.
Elekta and DCA Design International Ltd have won theGood Design® Award 2018 for Elekta Unity, the only magnetic resonance radiation therapy (MR/RT) system that integrates a 1.5T MRI scanner with an advanced linear accelerator and clinical software. The U.S.-based award is the world’s most prestigious, recognized and oldest Design Awards program.
Why is this important?
The MR-linac is arguably one of the most important radiotherapy innovations of the last 50 years, enabling clear visualization of the tumor and surrounding healthy tissues during beam delivery and the ability to adapt the treatment in real time based on daily changes to the tumor’s position, size and shape.
MOSAIQ demonstrates Elekta’s continuing leadership in innovating technology solutions that streamline and simplify the delivery of radiotherapy treatments
Elekta’sMOSAIQ®Oncology Information System (OIS) received the 2019 Category Leader Award for Oncology in the 2019 Best in KLAS: Software and Services report. Awards are based on evaluations collected byKLAS, an independent research firm.
Why is this important?
“We are gratified that MOSAIQ has received this award for the seventh time, especially given that it is based on input from the customers who use MOSAIQ every day,” says Peter Gaccione, Executive Vice President, Region North & Latin America. “Cancer care is increasingly complex, not only with respect to the treatments that are available, but how these treatments are used in combination. Ensuring that cancer care is delivered in a safe, effective and coordinated manner is a growing challenge. Elekta is committed to improving cancer patients’ care and outcomes. The ongoing recognition of the important role that MOSAIQ plays in helping our customers achieve their therapeutic, administrative and regulatory needs is tangible evidence that our innovations are advancing cancer care.”
To learn more about MOSAIQ, visitwww.neump.com/software-solutions/.
Elekta and DCA Design International Ltd have won the prestigiousHuman Factors and Ergonomics (HFES) Stanley H. Caplan User-Centered Product Design Award 2018for Elekta Unity, the company’s MR-linac. Elekta Unity combines high-field MRI, precision radiotherapy and intelligent software, enabling clinicians to see what they treat in real time.
Why is this important?
Elekta and the seven Elekta MR-linac Consortium partners invested tremendous time and resources in the design and development of Elekta Unity to ensure a solution that accounts for the needs of both patients and healthcare providers. A wide range of tools from the fields of human factors and design research were used to analyze data collected during the Elekta Unity design phase. These data were leveraged to inform product design. The award recognizes outstanding and innovative practice in product design. The result was a commercially available system, which received CE-mark in June 2018. To learn more, visitwww.neump.com/unity
Elekta and DCA Design International Ltd are the winners of this year’siF DESIGN AWARD, a world-renowned design prize, for Elekta’s MR-linac, Elekta Unity. The system is the only radiation therapy delivery system that integrates 1.5 Tesla MRI with precision radiotherapy technology – allowing physicians to image anatomy while simultaneously delivering therapeutic radiation beams to treat cancer.
Why is this important?
Elekta Unity was among 6,400 entries from 54 countries in the If DESIGN AWARD competition, one of the most prestigious and largest design competitions in the world. Elekta, in collaboration with the seven Elekta MR-linac Consortium institutions, worked tirelessly to overcome the technical barriers associated with integrating radiotherapy with real-time high-field MRI. Elekta Unity represents the first-ever high-field MR-linac, which allows clinicians to not only see what they treat, but to adapt therapy based on what is visualized with real-time MRI. To learn more, visit www.neump.com/unity
In the China Medical Equipment Data 2017 survey of medical equipment data and after-sales service, Elekta won the following awards: Most Recommended Brand by Users, TOP 1 After-sales Service Satisfaction in total ranking, TOP 1 After-sales Service Satisfaction in tertiary hospitals and Best After-sales Service in Linear Accelerator. The survey was co-organized by Health News and Medical Engineering Society of the Chinese Medical Association.
Why is this important?
The recognition and satisfaction in after-sales service has become among the most important assessment criteria during project negotiation and hospital purchasing. Moreover, a high level of after-sales service leads to an enhanced customer experience and higher customer loyalty. This is the second year in a row that Elekta China was ranked as TOP 1 After-sales Service Satisfaction.
Elekta’sMOSAIQ®Oncology Information System (OIS) received the 2017 Category Leader Award for Oncology in the 2017 Best in KLAS: Software and Services report. Awards are based on evaluations collected byKLAS, an independent research firm.
Why is this important?
“Elekta is honored to be recognized by KLAS for the sixth time and we attribute our success to our deep commitment to providing physicians and hospitals with highly customized and automated systems that can be deployed across multiple clinical centers,” said Bill Yaeger, Elekta’s Executive Vice President, Region North America. “MOSAIQ is more than an electronic health record – it’s an open, scalable, patient-centric system that facilitates insights and continuous learning. With MOSAIQ, our customers gain insight into how to optimize their workflows and treatment paradigms, enabling ongoing improvements in safety, efficiency and quality.”
To learn more about MOSAIQ, visitwww.neump.com/MOSAIQ.
Elekta has been awarded its fourth Queen’s Award in as many years. This year, the company is being honored with the Queen’s Award for Innovation 2015. The Queen’s Awards for Enterprise are the UK’s highest accolade for business success. The winners are announced each year on April 21, Her Majesty The Queen’s birthday. The corporate awards recognize outstanding achievements by UK companies in three categories: International Trade, Innovation and Sustainable Development. The award acknowledges Elekta’s 40-year history of developing radiotherapy equipment for the treatment of cancer.